The Clinical Analysis Of198Cases Of Triple Negative Breast Cancer

Female breast cancer is one of the most common malignant tumor, aserious threat to women’s health and life. Early screening is an effective meanto reduce breast cancer incidence and mortality. Breast cancer has a highheterogeneity, there is a great deal of difference Whether on morphology,immunophenotype in the organization or on biological behavior and treatment.More wide range with the development of molecular biology and theapplication of gene chip technology. We found that the gene expressionprofiles of Breast cancer are associated with their specific clinical features.Clear expression of genes in breast cancer、Determine the specific pathology ofit，can make us know more about the clinical features of breast cancer. We canmake the different treatment in the different pathological types of breast cancer,and we can also make the evaluation of different prognosis of breast cancer.Perou C． M had breast cancer classification through using cDNAmicroarray technology and the method of Cluster Analysis. The type of Lminalmeans the tumor gene expression of ER-positive breast duct epithelial cells andencoded protein gene-positive. Based on ER gene expression levels,productivity, can be divided into Lminal a and Lminal b-type. The type of thetumor gene expression of ER-negative can be divided into： HER-2over—expression subtype，normal breast—like subtype，basal—like subtype.As a subtype of breast cancer, basal-like breast cancer means have theexpression of the cells of basal-like, and also have the different levels ofCytokeratin positive expression Epidermal growth factor receptor (EGFR) orCK5\6, CK14, CK17. TNBC also a type of the breast cancer, and it have theER-negative, PR-negative and Her-2-negative. Clinical features and pathological types of triple-negative breast cancer in many similarcharacteristics with the basal-like breast cancer, but staggered overlap, is notthe same as. In addition, TNBC and breast cancer susceptibility gene1(breastcancer susceptibility gene l,BRCAl) there is a significant correlation, it kind ofbreast cancer and breast cancer susceptibility gene1correlation between moresimilarities also exist. Homologies of TNBC has a very high, and as a separateentity owned and other breast cancer subtypes of pathological and clinicalfeatures of the different, such differentiation of breast cancer is often poor.TNBC accounts for about breast cancer in general10%~20.8%, good for youngwomen before menopause under40years of age. Such unique clinical andpathological characteristics of breast cancer, TNBC prognosis is poor.Compared with other types of breast cancer, this high rate of local recurrenceand distant metastasis of breast cancer, especially in visceral metastases, brainmetastases are common. In case of recurrence and metastasis, prognosis isextremely poor. Three negative breast cancer was ER, PR and epidermalgrowth factor hormone antibodies HER-2were negative, hormone therapy andnon-targeted therapy drugs for HER-2for its effects are not ideal.Chemotherapy drugs although it has certain effect, but because of its earlyrecurrence and metastasis of its own characteristics, with short lifetimes,prognosis is poor.Analysis of clinical characteristics of three-negative breast cancer, we’vegathered between January2006visit to Sino-Japanese friendship Hospital ofJilin University, were confirmed through pathology,1644lines associated withbreast cancer surgery patients ’ clinical information. Immunohistochemicalanalysis of expression of ER and PR, HER-2are not three negative198casesof breast cancer (11.9%), three negative retrospective analysis of the clinicalfeatures of patients with breast cancer. Found that, compared to the Group ofTNBC and non-TNBC group, the age of small, patient age <50of138cases, 69.6%for751cases outside the Group of TNBC,51.9%; There is a familyhistory of the higher rate of TNBC, for14cases of TNBC group,7.1%,non-TNBC for28cases,1.9%; The large tumor size, group of TNBC≥5cm,38,and19.1%, for260cases outside the Group of non-TNBC,17.9%; Axillarylymph node Metastasis occurs when the high rate of its operation, TNBC groupof130cases,65.7%, non-TNBC group of684cases,41.1%; Axillary lymphnode metastasis in tumor size and, in a group of TNBC, when tumors <2cm indiameter, and its lymph node metastasis rate of50%; When you are>5cm indiameter, and its lymph node metastasis rate is83.0%(P<0.001); Regardless oftumor size, lymph node metastasis rate is higher than TNBC. In terms of EGFRexpression, expression of three yin and three Yin group and non-group rate and57.6%respectively: three Yin group, a total of198patients, EGFR-positive114people, their age, menstrual status and positive expression, regardless of thesize, type and grade of pathology tumor (p>0.05), but associated with lymphnode metastases or not. In patients with non-TNBC and TNBC group, therewas no significant difference in pathological, but graded higher. In addition,triple-negative breast cancer patients in surgery and postoperative radiotherapyand chemotherapy, and non-TNBC patients, there was no significant difference.Conclusion: In summary, three negative breast cancer due to molecularpathology and genotypes of promotion and use, more and more people areconcerned about. Patients with this type of breast cancer with younger,pathological staging high, highly malignant, early recurrence, metastasis andprognosis generally poor clinical features. For its own unique Clinicalpathological and molecular characteristics, present related research has beencarried out in some of the targeted treatment of, look forward to working withthe deepening of the research, three negative breast cancer treatment morechoices, making three negative prognosis in breast cancer patients can beimproved.